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Background: Mortality rates from lung cancer are known to vary considerably
between countries. Differences in patients, disease, investigation and treatment are
thought to account for some survival shortfalls but it is not known whether
differences in collection or processing of data also contribute.
Methodology: We searched recognised sources where information regarding
mortality rates have been published for the United Kingdom, Europe and United
States (US). Data regarding patient selection, demographics and mortality rates
were extracted.
Results: Published international 5-year survival for patients with lung cancer varies
from 5% to 16%. The survival figures quoted in the literature are based on data which
varies widely in its collection and statistical analysis and this information is not
always in the public domain. Data from the US suggests an overall 5-year survival
rate of up to 16% although this figure covers only a quarter of the general population
and excludes patients without histological confirmation. Many European countries
report higher mortality rates although in most, data includes patients without
proven histology. European datasets have variable population coverage.
Conclusion: Selective data collection and variable population coverage may
account for some of the differences in lung cancer survival between countries.
More transparent description of data collection and analysis would be helpful butElsevier Ltd. All rights reserved.
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comparisons in mortality rates.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Lung cancer is the leading cause of cancer death in
European men. In the United Kingdom (UK), it has
now superseded breast cancer as the leading cause
of cancer death in women.1,2 Despite advances in
many areas of oncology, lung cancer survival figures
remain disappointingly poor1,3 and it is well
documented that survival rates in the United States
(US) and some European countries are significantly
greater than those achieved in the UK and
Scandanavia.1,4 As a result, there has been con-
siderable debate as to the cause of the observed
survival inequalities.5–7 For example, differences in
eligibility for curative intervention, and accessi-
bility of investigations and treatment have all been
considered as potential explanations. As a conse-
quence, government bodies in the UK and Denmark
have endeavoured to address the issues raised.8–11
To date, there has been little discussion of the
differences in data collection in the overall inter-
pretation of lung cancer survival figures. Indeed, it
stands to reason that the proportion of the national
population covered in a database, the inclusion of
patients with unproven histology and the statistical
correction to produce relative survival could
significantly alter results. The purpose of this study
is to determine whether factors such as these might
contribute to international variations in documen-
ted survival.
Methodology
The most up to date published survival data from
the UK, Europe and the US were firstly identified.
Following this, all authors independently searched
for information regarding 5-year survival rates,
collection period, the proportion of patients having
histological confirmation and population demo-
graphics.Results
United States
In the US, the National Cancer Institute (NCI) was
found to be the primary source of survival figuresfor all cancers and publishes 5-year survival
collected from the surveillance, epidemiology,
and end results (SEER) program. It currently
collects cancer incidence and survival data from
14 population-based cancer registries and three
supplementary registries.4 SEER calculates relative
survival using survival figures from the US general
population of the same age sex and race. The
statistical basis of the SEER survival calculations for
lung cancer is not in the public domain.
The overall 5-year survival for the whole SEER
population was 15.2%.4 Only patients with a
histological diagnosis of small cell (11,306) or
non-small cell (64,035) lung cancer were included.
These data incorporate only 26% of the US popula-
tion and the inference is that this subgroup is a only
a reflection of total US population in terms of
wealth and education.4
England and Wales
For England and Wales, Cancer Research UK 2000
provided the source of information. A 5-year age
standardised survival of 6% for lung cancer was
reported between 1996 and 19992 All patients
—irrespective of having a histological diagnosis—
were included, with nearly 100% of the national
population represented in the database.
Scotland
For Scotland, data were obtained from Scottish
health statistics website (www.isdscotland.org).
The 5-year age-standardised relative survival rates
were similar to the survival rates for England and
Wales (Table 1).2,12 All histological types of
lung cancer—including those without proven
histology—were included and the database in-
cluded virtually 100% of the population.
Northern Ireland
For Northern Ireland, the cancer registry data
provided detailed mortality data.13 The Northern
Ireland Cancer Registry published a comprehensive
report encompassing incidence and mortality sta-
tistics for all cancers in their population (Table 1).13
The 5-year relative survival for patients with lung
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Table 1 Comparison of international lung cancer survival statistics.
Country Time period % of population
in database
Exclusions from the 5-
year survival statistic
5-year relative survival (%)
Male Female
United States 1995–2000 26 Patients without proven
histology
Whites 13.7 Whites 17.4
Black 11.9 Blacks 15.4
England and
Wales
1996–1999 63 None 6 6
Scotland 1992–1996 100 None 5.7 6
Northern
Ireland
1996–1999 100 None 9.5 10.2
Austria 1990–1994 8 None 13.4 16.0
France 1990–1994 3 None 13.1 15.9
Germany 1990–1994 2 None 10.8 10.5
Spain 1990–1994 15 None 12.4 12.8
Denmark 1990–1994 100 None 6.1 5.9
C.A. Butler et al.1644cancer diagnosed between 1996 and 1999 was
higher than England and Wales (Table 1). The
breakdown of histological subtype in this popula-
tion was 58% for non-small cell and 14% for small
cell. Twenty-seven percent of the population group
did not have a histological diagnosis. As expected,
5-year survival varied between patients with non-
small cell lung cancer, small cell lung cancer and
those with unknown histology; respective values
were 13.1%, 3.2% and 4%.Europe
For other European countries, EUROCARE provided
relevant data. The collection and statistical analy-
sis of these data are well described and in the
public domain.1 The EUROCARE 3 study was carried
out between 1990 and 1994, with a minimum
follow-up to 1998 to measure survival from cancer
across a large number of European countries. The
EUROCARE 3 report did acknowledge that there
were differences in the quality of data provided by
the European cancer registries in terms of disease
definition, case collection, and follow-up. Inade-
quate follow up of vital status may contribute to
apparent survival advantages in Austria and Spain
where deaths may be missed.14 The most favour-
able 5-year survival for males and females was
observed in Austria, Spain and France (Table 1) with
an overall European survival rate of 9.7% and 9.6%
for males and females, respectively.1 Survival was
poor in some Eastern European countries but also in
Denmark and in the UK. No comparisons between
race or histological subtypes were made in this
study. However, all cases including those without
proven histology were included. Information onmicroscopic verification was provided, with most
registries verifying over 70% of their lung cancer
cases. There was wide variation in the proportion
of the national population included in the data.
In general, those datasets reporting the best
survival included lower proportion of the national
population.Discussion
The international variation in published survival
figures for lung cancer is a concern for patients and
professionals alike. We have highlighted that
published 5-year survival rates are markedly higher
in the US than in the UK and some European
countries. The literature suggests that this may be
due to real differences in patients, disease,
investigation and treatment,1,6,15–17 although it
seems likely that differences in the collection and
presentation of data may also contribute. For
frequently quoted figures such as those coming
from SEER, which is the principal source of survival
figures for the US, not all the methodology of data
collection and statistical analysis is in the public
domain. Where it is available, figures are often
quoted without reference to the differences in data
collection and processing.
In the UK over the last decade, health care
professionals have worked with government bodies
to identify and address survival shortfalls.9,18 It has
been suggested that the UK is unable to offer the
same level of care for cancer as other European
countries because of sub-optimal numbers of radio-
therapists and medical oncologists.6 Indeed, in one
study, the mean total delay from presentation to
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respiratory physician to assess and subsequently
investigate the patient considered to be the main
rate limiting step.19 In another study, a single-centre
prospective audit on lung cancer waiting times
demonstrated that 21% of potentially curable
patients became incurable while waiting for appro-
priate treatment,19 while tumour control in small
cell lung cancer may be also adversely affected by
prolonged waiting times.17 No direct international
comparisons of investigation and treatment delays
have been made and the contribution made to
survival shortfalls are therefore difficult to quantify.
The use of radical treatment varies both nation-
ally and internationally, and surgical resection
rates in the UK have come under recent scrutiny.
The most optimistic figures suggest that less than
20% of patients presenting with lung cancer have
curable disease.9 The published rate for surgical
intervention for lung cancer in the UK is between
10–11%,9 although department of health guidelines
suggest that 20% of individuals with non-small cell
lung cancer should be suitable for surgery.9 Some
evidence suggests that in some parts of Europe and
the US the surgical resection rate is almost
30%.20,21 There are few data describing the number
of patients receiving radical radiotherapy or
whether radiotherapy delivered is the more effec-
tive continuous hyperfractionated accelerated
radiotherapy (CHART) or more conventional radical
radiotherapy.22 Furthermore, no appropriate data-
set exists on which to base an accurate assessment
of the number of patients amenable to surgery or
radical radiotherapy at presentation.
Elsewhere in the European Union, the EUROCARE
3 study reported that for lung cancer (and many
other common cancers), even the most favourable
survival rates failed to reach the corresponding
least favourable rates quoted in the SEER data-
base.1,4 The EUROCARE study also noted that most
European countries provided nationwide access to
healthcare, whereas a significant proportion of US
citizens have no or sub-optimal health insurance.
Since the group without health insurance is likely to
be over-represented among lung cancer patients, it
is therefore difficult to understand why the US
leads survival statistics.1
Is it possible that apparent survival differences
may result from differences in data or its presenta-
tion? EUROCARE 3 remarks that differences in
registry coverage and death certificate only regis-
tration may alter survival. It is clear that compar-
isons made between countries need to include a
description of data and its analysis. The proportion
of the population included in a cancer registry
differs widely between countries as does themethod of data collection. The statistical methods
used for standardisation for age and race also differ
between international data sets.23 The SEER data-
base includes 26% of the US population,24 whereas
the countries included in the EUROCARE 3 database
vary between 2.8% and 100% (Table 1).1 In Spain,
which has one of the most favourable EU 5-year
survival outcomes, the population coverage is only
14.5%.1 Follow up of patients in Spain is also known
to be less complete. In the EUROCARE study
relative survival is calculated by the Hakulinen
method.25
The omission of patients without histology in the
SEER database is likely to lead to more favourable
US survival statistics. Twenty-seven percent of the
Northern Ireland population with lung cancer did
not have a histological diagnosis and the 5-year
survival in this group was 4%, compared to 13.1% for
the non-small cell subgroup. Other UK cancer
registries do include all cases diagnosed as lung
cancer with or without histology. The impact of
excluding patients without histology from the data
will depend on the rate of histological confirmation
within the population. EUROCARE 2 illustrates the
varying rates of histological confirmation within
Europe and goes on to demonstrate survival
differences between patients with the same con-
firmed histology suggesting that within Europe
the interaction between histology and survival is
complex.15
In conclusion, large variations in published
survival figures between countries for lung cancer
are well documented and require further explana-
tion. Many of these variations may relate to
differences in patients, disease stage at presenta-
tion, in diagnosis or in treatment. As our study
suggests, some important differences are also likely
to relate to collection and presentation of data. A
greater emphasis on the use of comparable data
may help clarify and address real survival short-
falls. In the future, before valid direct comparisons
can be made between different countries and
continents in terms of lung cancer survival rates,
it is imperative that similar methods of data
collection and presentation are employed along
with ensuring similar—and indeed comparable—
populations are evaluated. National and interna-
tional bodies involved in the processing of mortality
rates for any type of cancer should ideally attempt
to employ similar strategies, with the ultimate aim
of identifying and addressing shortfalls in optimum
patient care. Moreover, perhaps there is a role for
an international body to develop a way of standar-
dising the description of international datasets in
turn making any differences in published cancer
survival rates easier to interpret, more transparent
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